Septerna (SEPN) director granted 15,000 options for RA Capital funds
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Septerna, Inc. reported that director Jake Simson received a grant of stock options covering 15,000 shares of common stock at an exercise price of $37.34 per share. The options vest in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided he continues to serve until that date.
Under an arrangement with RA Capital Management, L.P., Simson holds this option for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P. Any net cash or stock from exercising the option must be turned over to the adviser to offset advisory fees, and Simson disclaims beneficial ownership of the option and underlying shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Simson Jake
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 15,000 shares (Direct, null)
Footnotes (1)
- The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund") and R.A. Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Key Figures
Option grant size: 15,000 options
Exercise price: $37.34 per share
Underlying shares: 15,000 shares
+3 more
6 metrics
Option grant size
15,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$37.34 per share
Conversion or exercise price of granted options
Underlying shares
15,000 shares
Common stock underlying the option
Post-transaction derivative holdings
15,000 options
Total options following transaction
Option vesting date
June 26, 2027
Vests earlier of this date or next annual meeting
Option expiration
June 25, 2036
Expiration date of the stock option grant
Key Terms
Stock Option (Right to Buy), beneficial ownership, annual meeting of stockholders, advisory fees, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
beneficial ownership financial
"The Reporting Person therefore disclaims beneficial ownership of the option"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
annual meeting of stockholders financial
"the date of the Issuer's next annual meeting of stockholders"
advisory fees financial
"which will offset advisory fees owed by the Fund and the Nexus Fund III"
Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.
continued service financial
"subject to the Reporting Person's continued service to the Issuer"
FAQ
What did Septerna (SEPN) director Jake Simson receive in this Form 4 filing?
Septerna director Jake Simson received a grant of stock options for 15,000 shares of common stock at an exercise price of $37.34 per share. These options represent compensation and do not reflect an open-market share purchase or sale.
When do Jake Simson’s Septerna (SEPN) stock options vest?
The options vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual meeting of stockholders. Vesting requires Simson’s continued service to Septerna through the applicable vesting date as disclosed.
Who ultimately benefits from the Septerna (SEPN) stock options reported by Jake Simson?
The options are held for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P. Under an arrangement with RA Capital Management, L.P., any net cash or stock from exercising the options offsets advisory fees owed by those funds.
What is the expiration date of the Septerna (SEPN) stock options granted to Jake Simson?
The stock options expire on June 25, 2036, giving a long-dated window to exercise at the fixed price of $37.34 per share, subject to vesting and the existing arrangement with RA Capital Management, L.P.
How many Septerna (SEPN) derivative securities does the Form 4 show after this grant?
Following this grant, the Form 4 shows 15,000 stock options outstanding for Jake Simson. These options are tied to an equal number of underlying Septerna common shares, with no additional derivative positions listed in this specific filing.